Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.
about
Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signalingThe effects of oxidative stress on female reproduction: a reviewThioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicumValproic acid causes proteasomal degradation of DICER and influences miRNA expressionCell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylationPazopanib and HDAC inhibitors interact to kill sarcoma cells.BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 cells.Reactive oxygen species in normal and tumor stem cells.The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke Opisthorchis viverriniNovel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway.Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patientsSequence analysis, expression profiles and function of thioredoxin 2 and thioredoxin reductase 1 in resistance to nucleopolyhedrovirus in Helicoverpa armigera.Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based studyThioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.Wound healing essentials: let there be oxygenOxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.Redox control of the cell cycle in health and disease.Resolution of oxidative stress by thioredoxin reductase: Cysteine versus selenocysteine.HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cellsThe nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells.Treatment of epileptic seizures in brain tumors: a critical review.Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation.Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy.Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1α,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expression.From catalysts to bioactive organometallics: do Grubbs catalysts trigger biological effects?Targeting airway inflammation: PMX464 and the epithelial bulls eye.A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.β-Sitosterol targets Trx/Trx1 reductase to induce apoptosis in A549 cells via ROS mediated mitochondrial dysregulation and p53 activation.
P2860
Q28389739-C7D133E7-AEC1-4457-9083-55F721CF0ACCQ28392215-58E7AA47-B875-4398-A2BD-A2FF1AB5CC93Q28481160-7B8536C8-AD7B-41EC-8256-343042474CB5Q28537678-A9B6B5A8-4CBC-4FE5-BC53-E8C206F0E4A3Q30495932-FC8DAF10-7EA4-4762-89B8-A2C28D6E88A5Q33631472-367A513D-5AE3-481A-AAD2-06BF8FE462A1Q33643334-74B14CE0-F2AA-4706-A801-4C8018DA9E99Q33971323-1AA32E19-1AEB-460C-9076-579FE3E102DFQ34392752-F57D803A-195A-49F9-87D2-E1289C1BEC30Q34570642-69D3B87F-91DF-46DB-B28D-14B35DF85A6EQ34734032-AEE5DB2E-77EF-416D-993F-D39C330F9F66Q35624238-FD44C514-0AC5-4A92-ABBF-F6314A15B65FQ35937040-B6F89A80-43B8-4451-A500-70C36A3C1EACQ36209216-522DC878-BF6A-44D5-8990-ECD8264CCDCCQ36291060-DE8B944B-87C4-4050-909D-5CBB11F09CA2Q36312905-F8416E7B-655E-45C5-934D-17697DBE1563Q36393171-CF4A97AC-0422-400B-B41F-FCE2532C44EDQ37245938-8022C03C-BB1D-4D06-B472-83C174025172Q37482581-8AA3E2EF-7C2D-4122-BFB3-3D2EF94CD54AQ37510851-D2FC6134-2E80-4283-8C02-0CD32523FE86Q37629331-8180362A-E432-44BF-8A9B-E70069FDC800Q37683049-A863BA67-9E52-479A-9465-6845CA38439FQ38166575-57C3FEA2-D9FF-4DF5-BE67-D71A12179A4EQ38206723-D7D84C79-B2F2-409D-98D3-139F3800C1C1Q38535531-46404046-7811-4827-9B85-17973D42E5DCQ38826168-E79130E5-6927-41D1-A584-FB22143F37F6Q39121640-FC3FCDEE-7C04-439F-B2C2-C832A9F50CD2Q39254258-D9BF654D-AD12-479A-A35B-C6C9EB4A590DQ39477359-71EDE825-6040-4FD6-98B1-3DCAB36AF86BQ39964566-FE2D8242-F5CD-46CA-9D12-4698FB03B6DBQ47160397-4EA0A33D-C343-4AC6-84AC-8A9A0664D76DQ48120921-1D70D5CF-2970-4ADB-BCBA-2869221E6367
P2860
Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@en
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@nl
type
label
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@en
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@nl
prefLabel
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@en
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@nl
P2093
P1476
Thioredoxin and thioredoxin re ...... ar targets for cancer therapy.
@en
P2093
David Gius
Gil Bar-Sela
J Daniel Pennington
Kristi Muldoon Jacobs
Lunching Sun
Mark Mishra
P304
P356
10.2174/138161207782360528
P577
2007-01-01T00:00:00Z